AMBULATORY INFUSION  ·  SPECIALTY PHARMACY  ·  THERAPY MANAGEMENT
Home  /  Therapy Areas  /  Hematology
Therapy Area

Hematology.

Conditions we treat

  • Primary immunodeficiency (PID) — CVID, X-linked agammaglobulinemia, hyper-IgM syndromes
  • Immune thrombocytopenia (ITP)
  • Chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Hemophilia A and B
  • von Willebrand disease
  • Anemia of chronic disease
  • Iron deficiency anemia

Advanced hematologic therapies we deliver

TheraVite Health delivers and manages complex hematologic therapies, including immunoglobulin replacement, hemophilia factor products, and supportive care biologics across infusion and specialty pharmacy channels.

Infusion therapies (in-suite administration)

  • IVIg (intravenous immunoglobulin) — Privigen, Gammagard, Octagam, Gamunex-C; every 3 to 4 weeks typically
  • Iron sucrose (Venofer) — IV iron replacement
  • Ferric carboxymaltose (Injectafer) — IV iron replacement
  • Factor VIII concentrates — Advate, Eloctate, Adynovate, Esperoct, Jivi
  • Factor IX concentrates — BeneFix, Alprolix, Idelvion, Rebinyn

Subcutaneous therapies (specialty pharmacy dispensing & patient training)

  • SCIg (subcutaneous immunoglobulin) — Hizentra, Cuvitru, Xembify, Cutaquig
  • Hemlibra (emicizumab) — SC bispecific antibody for hemophilia A
  • Nplate (romiplostim) — SC TPO mimetic for ITP
  • Aranesp (darbepoetin alfa) — SC erythropoiesis-stimulating agent

Oral specialty medications

  • Promacta (eltrombopag) — oral TPO receptor agonist for ITP
TheraVite supports both administration (infusion) and dispensing (specialty pharmacy), with structured patient training for self-administered SCIg and hemophilia therapies.

What makes TheraVite’s approach distinct

IVIg and SCIg patients require particularly careful clinical management: pre-medication protocols, infusion rate titration, batch-to-batch variability awareness, and monitoring for infusion reactions. TheraVite’s multidisciplinary care model is well-matched to IG therapy because every visit includes a clinical review with your care team, not just nurse-administered infusion. Hemophilia patients benefit from our integrated approach because factor concentrates require both careful cold-chain management (specialty pharmacy strength) and acute administration capacity for breakthrough bleeds (infusion suite strength) — TheraVite delivers both from one team.

For referring providers

TheraVite handles prior authorization, benefits investigation, and payor credentialing for all therapies listed above. For drugs subject to limited distribution networks, we are pursuing manufacturer access in parallel with URAC accreditation. Contact us for current access status by drug.

Submit a referral →

For patients

If you have been prescribed any of the therapies above, TheraVite can typically begin treatment within 5 to 10 business days of receiving your prescription. We handle insurance verification, prior authorization, and patient onboarding so you can focus on your therapy.

Schedule an appointment →

Ready to get started?

Refer a Patient Schedule an Appointment